NCT05267886View on ClinicalTrials.gov

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

PHASE4RecruitingINTERVENTIONAL
Enrollment

346

Participants

Timeline

Start Date

March 5, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

December 31, 2026

Conditions
Shock, Cardiogenic
Interventions
DRUG

Dobutamine

Dobutamine administered according to its clinical dose stage for cardiogenic shock

DRUG

Milrinone

Milrinone administered according to its clinical dose stage for cardiogenic shock

DRUG

Normal Saline

Normal saline running at a standardized rate

Trial Locations (3)

55905

NOT_YET_RECRUITING

Mayo Clinic, Rochester

L8L 2X2

RECRUITING

Hamilton Health Sciences, Hamilton

K1Y4W7

RECRUITING

University of Ottawa Heart Institute, Ottawa

All Listed Sponsors
lead

Ottawa Heart Institute Research Corporation

OTHER